The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
126026504 12602650 4 F 2016 20160825 20160728 20160901 EXP JP-GLAXOSMITHKLINE-JP2016JPN107026 GLAXOSMITHKLINE 17.88 YR F Y 52.00000 KG 20160901 PH JP JP

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
126026504 12602650 1 PS LAMICTAL LAMOTRIGINE 1 Oral UNK UNK, 1D 525 MG Y 20241 TABLET
126026504 12602650 2 SS LAMICTAL LAMOTRIGINE 1 Oral 25 MG, 1D 525 MG Y 20241 25 MG TABLET QD
126026504 12602650 3 SS LAMICTAL LAMOTRIGINE 1 Oral 50 MG, 1D 525 MG Y 20241 50 MG TABLET QD
126026504 12602650 4 SS LAMICTAL LAMOTRIGINE 1 Oral 25 MG, 1D 525 MG Y 20241 25 MG TABLET QD
126026504 12602650 5 SS DEPAKENE VALPROIC ACID 1 Oral 400 MG, BID 7200 MG Y 0 400 MG BID
126026504 12602650 6 C ABILIFY ARIPIPRAZOLE 1 3 MG, 1D 135 MG 0 3 MG QD
126026504 12602650 7 C ABILIFY ARIPIPRAZOLE 1 6 MG, 1D 135 MG 0 6 MG QD
126026504 12602650 8 C ABILIFY ARIPIPRAZOLE 1 12 MG, 1D 135 MG 0 12 MG QD
126026504 12602650 9 C ABILIFY ARIPIPRAZOLE 1 6 MG, 1D 135 MG 0 6 MG QD
126026504 12602650 10 C SEROQUEL QUETIAPINE FUMARATE 1 100 MG, 1D 200 MG 0 100 MG QD
126026504 12602650 11 C FERROUS SULFATE. FERROUS SULFATE 1 210 MG, 1D 2730 MG 0 210 MG QD
126026504 12602650 12 C BELSOMRA SUVOREXANT 1 15 MG, 1D 135 MG 0 15 MG QD

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
126026504 12602650 1 Bipolar disorder
126026504 12602650 5 Bipolar disorder

Outcome of event

Event ID CASEID OUTC COD
126026504 12602650 HO
126026504 12602650 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
126026504 12602650 Blister
126026504 12602650 Conjunctival hyperaemia
126026504 12602650 Glossodynia
126026504 12602650 Headache
126026504 12602650 Lip erosion
126026504 12602650 Lip swelling
126026504 12602650 Ocular hyperaemia
126026504 12602650 Oral herpes
126026504 12602650 Pyrexia
126026504 12602650 Rash
126026504 12602650 Rash papular
126026504 12602650 Rash pruritic
126026504 12602650 Somnolence
126026504 12602650 Stevens-Johnson syndrome

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
126026504 12602650 2 20160428 20160502 0
126026504 12602650 3 20160502 20160506 0
126026504 12602650 4 20160506 20160516 0
126026504 12602650 5 20160506 20160520 0
126026504 12602650 6 20160427 20160502 0
126026504 12602650 7 20160502 20160506 0
126026504 12602650 8 20160506 20160513 0
126026504 12602650 9 20160513 20160516 0
126026504 12602650 10 20160513 20160516 0
126026504 12602650 11 20160502 20160516 0
126026504 12602650 12 20160506 20160516 0